Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.41 |
| ▸ | RAB9A | P51151 | 7/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.38 |
| ▸ | MAPT | P10636 | 6/20 | 0.38 |
| ▸ | GLA | P06280 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.37 |
| ▸ | MEN1 | O00255 | 4/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | TP53 | P04637 | 4/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | PDE2A | O00408 | 2/20 | 0.34 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7841262 | 0.84 | RAB9A (0.39) | NPC1RAB9AALDH1A1MAPTGLA | |
| SCHEMBL973209 | 0.82 | IKBKB (0.40) | NPC1RAB9AALDH1A1MAPTGLA | |
| SCHEMBL7094488 | 0.82 | RAB9A (0.38) | NPC1RAB9AALDH1A1MAPTGLA | |
| SCHEMBL4349529 | 0.82 | BACE1 (0.36) | MAPTMEN1KMT2AKDM4ETSHR | |
| SCHEMBL71079 | 0.81 | NPC1 (0.41) | NPC1RAB9AALDH1A1MAPTGLA | |
| SCHEMBL7088775 | 0.81 | NPC1 (0.41) | NPC1RAB9AALDH1A1MAPTGLA | |
| SCHEMBL3859298 | 0.81 | NPC1 (0.41) | NPC1RAB9AALDH1A1MAPTGLA | |
| SCHEMBL9690618 | 0.81 | NPC1 (0.41) | NPC1RAB9AALDH1A1MAPTGLA | |
| SCHEMBL3735368 | 0.81 | RAB9A (0.45) | NPC1RAB9AALDH1A1MAPTGLA | |
| SCHEMBL195410 | 0.81 | ALDH1A1 (0.42) | NPC1RAB9AALDH1A1MAPTGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1458392-B9 | ACRIDONES AS INHIBITORS OF IMPDH ENZYME | BRISTOL MYERS SQUIBB CO (US) | 2010-07-28 | — | — | EP | disclosed |
| EP-1458392-B1 | ACRIDONES AS INHIBITORS OF IMPDH ENZYME | BRISTOL MYERS SQUIBB CO (US) | 2009-09-02 | — | — | EP | disclosed |
| US-7312209-B2 | Acridone inhibitors of IMPDH enzyme | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-25 | — | — | US | disclosed |
| US-20060241108-A1 | Substituted phenoxazines and acridones as inhibitors of AKT | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2006-10-26 | — | — | US | disclosed |
| WO-2006094207-A2 | SUBSTITUTED PHENOXAZINES AND ACRIDONES AS INHIBITORS OF AKT | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2006-09-08 | — | — | WO | disclosed |
| US-20040053955-A1 | Acridone inhibitors of IMPDH enzyme | BRISTOL-MYERS SQUIBB COMPANY | 2004-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053955-A1 | Acridone inhibitors of IMPDH enzyme | IMPDH2, IMPDH1, XDH | NPC1 1935/4885RAB9A 3964/4885ALDH1A1 39/4885 |
| US-20060241108-A1 | Substituted phenoxazines and acridones as inhibitors of AKT | AKT1S1, AKT3, PIK3CA | NPC1 3202/4885RAB9A 3947/4885ALDH1A1 3003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.